Endoglin-targeted cancer therapy.
Seon
Ben K
BK
Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. ben.seon@roswellpark.org
Haba
Akinao
A
Matsuno
Fumihiko
F
Takahashi
Norihiko
N
Tsujie
Masanori
M
She
Xinwei
X
Harada
Naoko
N
Uneda
Shima
S
Tsujie
Tomoko
T
Toi
Hirofumi
H
Tsai
Hilda
H
Haruta
Yuro
Y
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000494:pharmacology*; D015703:Antigens, CD / Q000378:metabolism*; D002986:Clinical Trials as Topic; D000071063:Endoglin; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology / Q000494:pharmacology*; D000922:Immunotoxins / Q000276:immunology / Q000494:pharmacology*; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D018796:Immunoconjugates; D000922:Immunotoxins; D011956:Receptors, Cell Surface; C579557:carotuximab